More than 10,000 hematopoietic cell transplantations (HCT) are performed annually in the United States as a potentially curative treatment for over 70 life-threatening illnesses including hematologic cancers, genetic disorders, and other diseases. Despite significant advances in supportive care and improvements in HCT outcomes, one in every three patients may succumb to HCT-related toxicities, half of which are not related to graft-versus-host disease (GVHD). Following the successful examples of the international symposia focusing on GVHD and relapse after HCT, ASBMT leaders Sergio Giralt, MD, and Miguel-Angel Perales, MD, are holding the '1st International Symposium on Hematopoietic Cell Transplantation-Related Toxicities.’
This symposium will bring together experts and thought leaders from around the world in the fields of HCT and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT in order to identify best practices to both prevent and treat HCT-related toxicities. Over the 2-day symposium, speakers and attendees will also convene in dedicated sessions that will facilitate collaborative efforts in planning future research aimed at mitigating serious toxicities, reducing symptom burden, and improving patients’ outcomes.
The symposium will be held April 27-28, 2018 at Memorial Sloan Kettering Cancer Center in New York, NY. Additional information and registration can be found online at: www.mskcc.org/Toxicities.